When applied to subjects with metabolic syndrome (MS) or type 2 diabetes (t2DM) the therapy improves the diverse parameters inherit to metabolic syndrome (MS) and type 2 diabetes (t2DM)—inflammation, hypertension, glycemia, dyslipidemia, abdominal obesity, body weight, and insulin signaling. This evidence concerns the gene INS and type 2 diabetes mellitus.